Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH